Ernexa (ERNA) Director Bristol James Arthur Receives Option Awards

What Happened

• Bristol James Arthur, a director of Ernexa Therapeutics Inc. (ERNA), received two derivative equity grants on 2026-08-31 representing the right to acquire a total of 13,403 shares (8,320 and 5,083). The Form 4 lists a $0.00 per-share exercise/price and reports these as awards (derivative securities), not open-market purchases or sales.

Key Details

• Transaction date: 2026-08-31; Form 4 filed: 2026-09-01 (timely).
• Instruments: Derivative awards (options) underlying 8,320 and 5,083 shares; total underlying shares = 13,403.
• Price/value reported on Form 4: $0.00 per share (total $0 reported at grant).
• Vesting/terms from footnotes:
  • F1: For one grant, one-third vests on the first anniversary of the grant date, then the remainder vests in 24 substantially equal monthly installments (subject to continued service).
  • F2: The other grant represents options issued in lieu of prorated 2026 director cash compensation under the Director’s Compensation Plan and the Issuer’s 2026 Omnibus Equity Incentive Plan; these options vest 100% on December 31, 2026 (subject to continued service).
• Shares owned after transaction: not specified in the excerpt of the filing.
• Filing timeliness: no late filing indicated.

Context

• These were compensation awards (options) to a director, not sales or open-market purchases. Derivative awards typically vest over time and give the holder a right to acquire shares later; they do not represent immediate share sales. For retail investors, such grants are routine director compensation and should be viewed as part of pay arrangements rather than a direct buy/sell signal.